title: Efinaconazole and Tavaborole.
abstract: OBJECTIVE
  The purpose of this article is to review the safety, efficacy, and role of efinaconazole and tavaborole in the treatment of onychomycosis.
  
  
  CONCLUSIONS
  Onychomycosis is a fungal infection of the nail caused by dermatophytes, yeasts, and nondermatophyte fungi. Distal and lateral subungual onychomycosis (DLSO) accounts for the majority of the cases. These infections cause structural damage to the nail which makes treatment difficult. Both oral and topical agents exist for the treatment of onychomycosis. Oral medications have generally been more effective, yet adverse effects and drug interactions limit their use in some patients. Food and Drug Administration (FDA)-approved agents in the United States for oral therapies include terbinafine, itraconazole, and griseofulvin. The only topical product available up to recently was ciclopirox.
  
  
  CONCLUSIONS
  This article will review efinaconazole and tavaborole, 2 new topical antifungal agents released in 2014.
authors.affiliation: 1 Lloyd L. Gregory School of Pharmacy, Palm Beach Atlantic University, West Palm Beach, FL, USA.
authors.forename: Mara
authors.initials: M
authors.lastname: Poulakos
authors.affiliation: 1 Lloyd L. Gregory School of Pharmacy, Palm Beach Atlantic University, West Palm Beach, FL, USA.
authors.forename: Yasmin
authors.initials: Y
authors.lastname: Grace
authors.affiliation: 1 Lloyd L. Gregory School of Pharmacy, Palm Beach Atlantic University, West Palm Beach, FL, USA.
authors.forename: Jade D
authors.initials: JD
authors.lastname: Machin
authors.affiliation: 1 Lloyd L. Gregory School of Pharmacy, Palm Beach Atlantic University, West Palm Beach, FL, USA.
authors.forename: Erin
authors.initials: E
authors.lastname: Dorval
mesh_terms: D000287:Administration, Topical; D000818:Animals; D000935:Antifungal Agents / Q000008:administration & dosage*; D001896:Boron Compounds / Q000008:administration & dosage*; D019086:Bridged Bicyclo Compounds, Heterocyclic / Q000008:administration & dosage*; D002986:Clinical Trials as Topic / Q000379:methods; D005533:Foot Dermatoses / Q000175:diagnosis / Q000188:drug therapy*; D006801:Humans; D008826:Microbial Sensitivity Tests / Q000379:methods; D014009:Onychomycosis / Q000175:diagnosis / Q000188:drug therapy*; D014230:Triazoles / Q000008:administration & dosage*
chemical_list: D000935:Antifungal Agents; D001896:Boron Compounds; D019086:Bridged Bicyclo Compounds, Heterocyclic; D014230:Triazoles; C431707:efinaconazole; C512998:tavaborole
keywords: antifungal; efinaconazole; onychomycosis; tavaborole